
In a recent study comparing treatments for sepsis with acute respiratory distress syndrome (ARDS), a combination of Sivelestat Sodium Hydrate (SSH) and Ulinastatin (UTI) was examined. The study involved 84 patients divided into control and observation groups, with the observation group showing a higher total effective rate. Patients receiving SSH and UTI had shorter mechanical ventilation and ICU hospitalization times and lower incidence of multiple organ dysfunction syndrome. Although the mortality rate did not significantly differ, the observation group demonstrated better lung injury scores, respiratory function, and reduced inflammation and oxidative stress. The study suggests that combining SSH with UTI benefits individuals with sepsis and ARDS by improving lung injury and reducing inflammation and oxidative stress.
Like
Save
Share